TMCnet News
CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary CholangitisNEWARK, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it will host a Key Opinion Leader (KOL) meeting on novel treatments for primary biliary cholangitis (PBC) on Wednesday, October 25, in New York City. The meeting will feature a presentation by key opinion leader (KOL) Professor Gideon Hirschfield, MD, PhD (University of Birmingham, UK), who will discuss the current and novel approaches to treating primary biliary cholangitis (PBC). Professor Hirschfield will be available to answer questions following the lunch. CymaBay's management team will also provide an update on results from their phase 2 study of seladelpar (MBX-8025) in patients with PBC that will be presented during the late-breaking session at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2017. Seladelpar is an orally administered potent and selective peroxisome proliferator-activated receptor delta (PPARd) agonist. The European Medicines Agency has granted CymaBay PRIority MEdicines (PRIME) status for MBX-8025 for the treatment of PBC. Professor Gideon Hirschfield is a Professor in the Centre for Liver Research at the University of Birmingham, UK, one of the largest such programs in Europe. Professor Hirschfield was previously a Staff Physician and Assistant Professor of Medicine at the University Health Network and University of Toronto, where he managed one of the largest autoimmune liver disease cohorts in North America. In conjunction with his colleague Prof. Kathy Siminovitch, he published the seminal genetic observations underpinning the IL-12 signaling axis as critical to the pathophysiology of PBC. He now divides his time betwee translational research in autoimmune liver disease and his clinical Transplant/Hepatology practice at the Queen Elizabeth Hospital Birmingham, where he manages some of the largest international cohorts of patients with PBC, primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH). This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. You can RSVP to attend by emailing Mac MacDonald at [email protected]. For those who are unable to attend in person, a live webcast and replay will be accessible at http://lifesci.rampard.com/20171025a/reg.jsp. About PBC About Seladelpar About CymaBay For additional information about CymaBay visit www.cymabay.com. Contact: |